Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.305 EUR -0.97% Market Closed
Market Cap: 32.7m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Intrinsic Value

SIGHT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.361 EUR. Compared to the current market price of 0.305 EUR, Gensight Biologics SA is Undervalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SIGHT Intrinsic Value
0.361 EUR
Undervaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gensight Biologics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SIGHT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SIGHT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Gensight Biologics SA

Provide an overview of the primary business activities
of Gensight Biologics SA.

What unique competitive advantages
does Gensight Biologics SA hold over its rivals?

What risks and challenges
does Gensight Biologics SA face in the near future?

Has there been any significant insider trading activity
in Gensight Biologics SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gensight Biologics SA.

Provide P/S
for Gensight Biologics SA.

Provide P/E
for Gensight Biologics SA.

Provide P/OCF
for Gensight Biologics SA.

Provide P/FCFE
for Gensight Biologics SA.

Provide P/B
for Gensight Biologics SA.

Provide EV/S
for Gensight Biologics SA.

Provide EV/GP
for Gensight Biologics SA.

Provide EV/EBITDA
for Gensight Biologics SA.

Provide EV/EBIT
for Gensight Biologics SA.

Provide EV/OCF
for Gensight Biologics SA.

Provide EV/FCFF
for Gensight Biologics SA.

Provide EV/IC
for Gensight Biologics SA.

Show me price targets
for Gensight Biologics SA made by professional analysts.

What are the Revenue projections
for Gensight Biologics SA?

How accurate were the past Revenue estimates
for Gensight Biologics SA?

What are the Net Income projections
for Gensight Biologics SA?

How accurate were the past Net Income estimates
for Gensight Biologics SA?

What are the EPS projections
for Gensight Biologics SA?

How accurate were the past EPS estimates
for Gensight Biologics SA?

What are the EBIT projections
for Gensight Biologics SA?

How accurate were the past EBIT estimates
for Gensight Biologics SA?

Compare the revenue forecasts
for Gensight Biologics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gensight Biologics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gensight Biologics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gensight Biologics SA compared to its peers.

Compare the P/E ratios
of Gensight Biologics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Gensight Biologics SA with its peers.

Analyze the financial leverage
of Gensight Biologics SA compared to its main competitors.

Show all profitability ratios
for Gensight Biologics SA.

Provide ROE
for Gensight Biologics SA.

Provide ROA
for Gensight Biologics SA.

Provide ROIC
for Gensight Biologics SA.

Provide ROCE
for Gensight Biologics SA.

Provide Gross Margin
for Gensight Biologics SA.

Provide Operating Margin
for Gensight Biologics SA.

Provide Net Margin
for Gensight Biologics SA.

Provide FCF Margin
for Gensight Biologics SA.

Show all solvency ratios
for Gensight Biologics SA.

Provide D/E Ratio
for Gensight Biologics SA.

Provide D/A Ratio
for Gensight Biologics SA.

Provide Interest Coverage Ratio
for Gensight Biologics SA.

Provide Altman Z-Score Ratio
for Gensight Biologics SA.

Provide Quick Ratio
for Gensight Biologics SA.

Provide Current Ratio
for Gensight Biologics SA.

Provide Cash Ratio
for Gensight Biologics SA.

What is the historical Revenue growth
over the last 5 years for Gensight Biologics SA?

What is the historical Net Income growth
over the last 5 years for Gensight Biologics SA?

What is the current Free Cash Flow
of Gensight Biologics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gensight Biologics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gensight Biologics SA

Current Assets 13m
Cash & Short-Term Investments 6.9m
Receivables 1.3m
Other Current Assets 4.7m
Non-Current Assets 2m
Long-Term Investments 519k
PP&E 1.4m
Intangibles 66k
Current Liabilities 16.9m
Accounts Payable 4.8m
Accrued Liabilities 1.6m
Other Current Liabilities 10.5m
Non-Current Liabilities 23m
Long-Term Debt 16m
Other Non-Current Liabilities 6.9m
Efficiency

Earnings Waterfall
Gensight Biologics SA

Revenue
2.4m EUR
Operating Expenses
-39.5m EUR
Operating Income
-37.1m EUR
Other Expenses
5m EUR
Net Income
-32.1m EUR

Free Cash Flow Analysis
Gensight Biologics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SIGHT Profitability Score
Profitability Due Diligence

Gensight Biologics SA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional Revenue Growth Forecast
ROE is Increasing
Negative 1-Year Revenue Growth
21/100
Profitability
Score

Gensight Biologics SA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

SIGHT Solvency Score
Solvency Due Diligence

Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
28/100
Solvency
Score

Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.364 EUR
19% Upside
Average
Price Target
0.388 EUR
27% Upside
Highest
Price Target
0.42 EUR
38% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SIGHT?

Click here to dive deeper.

Dividends

Gensight Biologics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for SIGHT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SIGHT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Gensight Biologics SA Logo
Gensight Biologics SA

Country

France

Industry

Biotechnology

Market Cap

31.5m EUR

Dividend Yield

0%

Description

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Contact

ILE-DE-FRANCE
Paris
74 Rue du Faubourg Saint-Antoine
+33176217220.0
www.gensight-biologics.com

IPO

2016-07-13

Employees

33

Officers

CEO & Director
Ms. Laurence Rodriguez
Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer
Dr. Jose-Alain Sahel M.D., Ph.D.
Scientific Founder & Chairman of Scientific Advisory Board
Prof. Botond Roska M.D., Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Constance L. Cepko Ph.D.
Chief Financial Officer
Mr. Jan Eryk Umiastowski
Chief Technical Officer
Mr. Scott Jeffers
Show More
Consultant
Dr. Barrett Katz CMO, M.B.A., M.D.
Chief Medical Officer
Dr. Magali Taiël M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one SIGHT stock?

The intrinsic value of one SIGHT stock under the Base Case scenario is 0.361 EUR.

Is SIGHT stock undervalued or overvalued?

Compared to the current market price of 0.305 EUR, Gensight Biologics SA is Undervalued by 16%.

Back to Top